Enzychem Lifesciences Corporation

KOSDAQ 183490.KQ

Enzychem Lifesciences Corporation EBIT Margin for the year ending December 31, 2023: -12.21%

Enzychem Lifesciences Corporation EBIT Margin is -12.21% for the year ending December 31, 2023, a 79.07% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Enzychem Lifesciences Corporation EBIT Margin for the year ending December 31, 2022 was -58.36%, a 32.91% change year over year.
Enzychem Lifesciences Corporation EBIT Margin for the year ending December 31, 2021 was -86.98%, a -26.51% change year over year.
Enzychem Lifesciences Corporation EBIT Margin for the year ending December 31, 2020 was -68.76%, a -31.91% change year over year.
Enzychem Lifesciences Corporation EBIT Margin for the year ending December 31, 2019 was -52.12%, a -14.15% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KOSDAQ: 183490.KQ

Enzychem Lifesciences Corporation

CEO	Ki-Young Sohn
IPO Date	April 5, 2017
Location	South Korea
Headquarters	aT Center
Employees	122
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Dental Care Pharmaceuticals

Description

Enzychem Lifesciences Corporation, a pharmaceutical company, focuses on the development of oral small molecule therapies for patients with unmet medical needs for oncology, metabolic diseases, and inflammatory diseases in South Korea. It is also developing potential therapies based on EC-18 technology platform to treat chemotherapy-induced neutropenia, chemoradiation therapy-induced oral mucositis, and acute radiation syndrome. The company was founded in 1999 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years